Starting Dose: 10 mg Once Daily
For an 84-year-old woman weighing 60 kg, start empagliflozin (Jardiance) at 10 mg once daily, taken in the morning with or without food 1. This is the FDA-approved starting dose and the dose used in cardiovascular outcomes trials 2, 3.
Key Dosing Considerations
Renal Function Assessment is Critical
Before initiating Jardiance, you must assess her estimated glomerular filtration rate (eGFR) 1:
- eGFR ≥45 mL/min/1.73 m²: Start 10 mg daily with no restrictions 2, 3
- eGFR 30-44 mL/min/1.73 m²: Can still initiate 10 mg daily for cardiovascular/kidney benefits, though glucose-lowering efficacy is reduced 4
- eGFR <30 mL/min/1.73 m²: Initiation not recommended for glycemic control; for heart failure indication, can initiate if eGFR ≥20 mL/min/1.73 m² 4, 5
The 2022 ADA/KDIGO consensus guidelines clarify that empagliflozin 10 mg daily is appropriate even with eGFR 30-44 mL/min/1.73 m², though the FDA label states use is "not recommended" below 45 mL/min/1.73 m² for glycemic control 4. The cardiovascular and kidney benefits persist at lower eGFR levels, which is why continuation is recommended once started 4.
Do Not Increase the Dose for Cardiovascular/Renal Benefits
The 10 mg dose provides full cardiovascular and renal protection—do not titrate up to 25 mg unless additional glucose lowering is specifically needed 3. The EMPA-REG OUTCOME trial demonstrated that both 10 mg and 25 mg doses produced similar cardiovascular benefits (38% reduction in cardiovascular death, 35% reduction in heart failure hospitalization) 6. There is no dose-response relationship for cardiometabolic outcomes 7.
Special Considerations for This Patient
Age and Weight Factors
At 84 years old and 60 kg, this patient requires heightened attention to:
Volume depletion risk: Elderly patients with lower body weight are at increased risk for intravascular volume contraction 4, 3, 1. Before starting:
- Correct any existing volume depletion 1
- Review and consider reducing diuretic doses if applicable 3
- Monitor blood pressure closely after initiation 1
Genital mycotic infections: Women have significantly higher risk (5.4-6.4% vs 1.5% placebo) 4. Counsel on daily genital hygiene measures 4.
Medication Adjustments at Initiation
If she is on other glucose-lowering medications:
- Insulin: Consider reducing total daily dose by ~20% to prevent hypoglycemia 3
- Sulfonylureas: Consider weaning or stopping to avoid hypoglycemia 3
- Other antihypertensives: May need dose reduction given empagliflozin's blood pressure-lowering effect (approximately -4 mmHg systolic, -2 mmHg diastolic) 8, 9
Critical Safety Warnings
Discontinue 3-4 days before any planned surgery to prevent postoperative euglycemic ketoacidosis 3. This is particularly important in elderly patients.
Sick day planning: Instruct her to stop empagliflozin during acute illness, prolonged fasting, or critical illness to mitigate ketoacidosis risk 10, 11.
Monitor for Fournier's gangrene: Though rare, this necrotizing fasciitis of the perineum requires urgent recognition—look for genital/perineal pain, tenderness, erythema, swelling with fever 1. Discontinue immediately if suspected.
Follow-Up Monitoring
After initiation:
- Reassess volume status and blood pressure within 2-3 days
- Check renal function and electrolytes at 2-3 days, then monthly for 3 months 12
- Monitor for genital mycotic infections (most common adverse effect in women) 1
- Assess glucose levels if on insulin or sulfonylureas
Once initiated, empagliflozin can be continued even if eGFR declines below the initiation threshold, as cardiovascular and kidney benefits persist 4, 5.